Stanislovas S. Jankauskas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stanislovas S. Jankauskas has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Fahimeh Varzideh
Department of Medicine (Division of Cardiology), Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York City, NY 10461, USA
2 shared publications - Gaetano Santulli
City University of New York
2 shared publications - Scott Wilson
Department of Medicine (Division of Cardiology), Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York City, NY 10461, USA
2 shared publications - Urna Kansakar
Department of Molecular, Cellular, and Biomedical Sciences, City University of New York, School of Medicine, Manhattan (F.V., T.G., S.S.J., U.K., S.P., G.S.).
2 shared publications - Vasvi Bhutani
Department of Medicine (Division of Cardiology), Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York City, NY 10461, USA
2 shared publications
Latest Publications
- Open Access
- 25 June 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (7) , 242
Correction: Bhutani et al. Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update. J. Cardiovasc. Dev. Dis. 2025, 12, 207
- 25 June 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (7) , 242
Open AccessCorrection: Bhutani et al. Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update. J. Cardiovasc. Dev. Dis. 2025, 12, 207
- Top Cited PapersOpen Access
- 30 May 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (6) , 207
Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update
Doxorubicin is an anthracycline chemotherapeutic that is widely used for treating various malignancies, including breast cancer, lymphomas, and sarcomas. Despite its efficacy, its clinical utility is limited by a well-documented risk of cardiotoxicity, which may manifest acutely or chronically. Doxorubicin works by intercalating DNA and inhibiting topoisomerase II, leading to DNA damage and cell death. However, this mechanism is not selective to cancer cells and can adversely affect cardiac myocytes. The introduction of doxorubicin into oncologic practice has revolutionized cancer treatment, but its cardiotoxic effects remain a significant concern. This systematic review aims to comprehensively examine the multifaceted impact of doxorubicin on cardiac structure and function through both preclinical and clinical lenses.
- 30 May 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (6) , 207
Top Cited PapersOpen AccessDoxorubicin-Induced Cardiotoxicity: A Comprehensive Update
Doxorubicin is an anthracycline chemotherapeutic that is widely used for treating various malignancies, including breast cancer, lymphomas, and sarcomas. Despite its efficacy, its clinical utility is limited by a well-documented risk of cardiotoxicity, which may manifest acutely or chronically. Doxorubicin works by intercalating DNA and inhibiting topoisomerase II, leading to DNA damage and cell death. However, this mechanism is not selective to cancer cells and can adversely affect cardiac myocytes. The introduction of doxorubicin into oncologic practice has revolutionized cancer treatment, but its cardiotoxic effects remain a significant concern. This systematic review aims to comprehensively examine the multifaceted impact of doxorubicin on cardiac structure and function through both preclinical and clinical lenses.